[CLSTR]
< Back to situations

Monitor this situation.

[SITUATION] · [ACTIVE] · [BUSINESS]

2 clusters · 13 sources · 6 days · First seen · Last updated

China biopharmaceutical industry growth

Overview

China is expanding its national health insurance coverage to include more innovative drugs, specifically targeting cancer, chronic, rare, and pediatric conditions. Since 2018, the National Healthcare Security Administration has added 949 medicines to the national insurance list, including 199 innovative drugs. Authorities also aim to shorten approval times and encourage private insurance coverage for clinically significant drugs.

This domestic policy support coincides with China’s emergence as a dominant force in the global biopharmaceutical ecosystem. China has become the world’s second-largest developer of innovative drugs, utilizing faster and more cost-effective clinical trials. The scale of this growth is evidenced by the value of Chinese out-licensing deals, which reached $115 billion in 2025.

While China’s influence reshapes global dealmaking, its rise has sparked debate in the United States regarding national security and research funding. Industry leaders have noted that China’s dominance makes it an “unavoidable factor” for global players, even as geopolitical complexities increase risks for Western companies engaging with the region.

Entities

China · Li Tao · Ministry of Industry and Information Technology · AstraZeneca · National Healthcare Security Administration

Timeline

  1. 1 day ago

    [BUSINESS] 2 sources
    China's biopharma rise reshapes global innovation and dealmaking

    China is transforming the global biopharma landscape through rapid innovation and massive out-licensing deals, prompting both strategic shifts by big pharma and national security debates in the US.

  2. 7 days ago

    [HEALTH] 11 sources
    China expands health insurance coverage for innovative drugs

    China is expanding national health insurance to cover more innovative drugs for cancer and rare diseases, while also boosting private insurance coverage and accelerating pharmaceutical approval processes.

Sources

cagliarilivemagazine.it · dialessandria.it · globaldata.com · ilfattonisseno.it · iltempo.it · italpress.com · laltravoce.com · pugliain.net · quotidianodelsud.it · quotidianodigela.it · supertvoristano.it · thetech.com · trapanisi.it